The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn’s disease
Abstract
Background Crohn's disease (CD) is a chronic inflammatory bowel disease usually diagnosed in early adult life and characterized by unpredictable flares and debilitating symptoms such as diarrhea, abdominal pain, and fever, which can interfere with a patient's ability to work and perform daily activities.Objective The aim of this study was to assess the validity, reliability, and responsiveness of the Work Productivity and Activity Impairment questionnaire in CD (WPAI:CD).Methods The WPAI:CD was tested in CD patients enrolled in a 26-week randomized clinical trial of cer-tolizumab pegol versus placebo. Discriminative validity of WPAI:CD absenteeism, presenteeism(reduced on-the-job effectiveness), overall work productivity loss (absenteeism + presenteeism), and activity impairment scores was assessed relative to 5 measures of disease severity and health status: CD Activity Index (CDAI), Short Form-36 physical component summary (PCS) and mental health component summary (MCS) scores, Inflammatory Bowel Disease Questionnaire (IBDQ), and the 5-dimensional EuroQoL health-related quality-of-life visual analog scale (EQ-VAS). Responsiveness was assessed by comparing changes in WPAI:CD scores from baseline to week 26 for patients in remission (CDAI <150 points) versus no remission. Standardized Response Means (SRMs) were calculated to evaluate the magnitude of the changes.Results A total of 662 patients (mean [range] age, 37.4 [18-77] years; male, 288 [43.5%]; white, 629 [95.0%]) were enrolled in the study. Patients with CD of the worst severity (CDAI > median) showed significantly higher impairment in work (+10.5%) and activities (+10.4%) versus patients with "best health" (no problems) (both, P < or = 0.001). Patients with "worst" IBDQ, PCS, MCS, and EQ-VAS scores also showed significantly higher impairments in work (IBDQ, VAS -24.2%; PCS, -24.1%; MCS, -15.9%; EQ-VAS, -16.5%) and activities (IBDQ, -23.3%; PCS, -21.8%; MCS, -16.5%; EQ-VAS, -17.2%) versus "best" scores (all, P < 0.05). There were significant differences between WPAI:CD impairment scores for patients in remission versus patients failing to achieve remission (P < 0.05). SRMs were small (ie, <0.5) in the nonre-mission group, and moderate to large (ie, >0.5) for patients in remission.Conclusions The discriminative validity, reliability, and responsiveness of the WPAI:CD were demonstrated. The WPAI:CD may be useful for evaluating drug impact on CD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Impact on health, work productivity, and daily life activities has been already described by qualitative studies (16-20) and costs of productivity loss has been estimated (21).”
From Quantification of the impact of endometriosis symptoms on health-related quality of life and work productivity (2011) · cites this paper as [19]
Citations
Cites
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071
Self-citationAssche, G. V., Dignass, A. U., Panés, J., Beaugerie, L., Karagiannis, J. A., Allez, M., Ochsenkühn, T., Orchard, T., Rogler, G., Louis, E. J., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.12.003 · Cited by 1,444
A New Measure of Health Status for Clinical Trials in Inflammatory Bowel Disease
Guyatt, G., Mitchell, A., Irvine, E. J., Singer, J., Williams, N., Goodacre, R. L., & Tompkins, C. (1989) · Gastroenterology · doi:10.1016/s0016-5085(89)80080-0 · Cited by 1,289
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P., Rutgeerts, P. J., Mason, D. H., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,141
Irvine, E. J., Feagan, B. G., Rochon, J., Archambault, A., Fedorak, R. N., Groll, A., Kinnear, D. G., Saibil, F. G., & McDonald, J. W. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90585-1 · Cited by 709
Loftus, C. G., Loftus, E. V., Harmsen, S. W., Zinsmeister, A. R., Tremaine, W. J., Melton, J. L., & Sandborn, W. J. (2006) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20029 · Cited by 638
Stange, E. F., Travis, S. P. L., Vermeire, S., Beglinger, C., Kupcinkas, L., Geboes, K., Barakauskiene, A., Villanacci, V., Herbay, A. V., Warren, B. F., et al. (2006) · Gut · doi:10.1136/gut.2005.081950a · Cited by 506
For the European Regulatory Issues on Quality of Life Assessment Group, Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., & Aaronson, N. K. (2002) · Drug Information Journal · doi:10.1177/009286150203600127 · Cited by 366
Research works printed but not linked: 4
- Ekbom, 1998, Cost to society of Crohn's disease, Res Clin Forums, 20, 33
- Joshua-Gotlib, 2004, Evaluation of the burden of illness in patients with mild to moderate Crohn disease, Drug Benefit Trends, 16, 600
- Wahlqvist, 2003, Resolution of upper gastrointestinal symptoms associated with chronic non-steroidal anti-inflammatory drug therapy has a positive impact on patient-reported productivity, Gastroenterology, 124, A107
- 2000, EQ-5D: A measure of heath-related quality of life developed by the EuroQol Group: User guide, EuroQol Group
Cited by
Sorted by citations
Peyrin‐Biroulet, L., Sandborn, W. J., Sands, B. E., Reinisch, W., Bemelman, W. A., Bryant, R. V., D’Haens, G., Dotan, I., Dubinsky, M. C., Feagan, B. G., et al. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,902
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P., Rutgeerts, P. J., Mason, D. H., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,141
Zhang, W., Bansback, N., Boonen, A., Young, A., Singh, A., & Anis, A. H. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3141 · Cited by 287
Fourquet, J., Báez, L., Figueroa, M., Iriarte, R. I., & Flores, I. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.04.095 · Cited by 262
“Impact on health, work productivity, and daily life activities has been already described by qualitative studies (16-20) and costs of productivity loss has been estimated (21).”
BackgroundPatient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease
Williet, N., Sandborn, W. J., & Peyrin–Biroulet, L. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.016 · Cited by 260
Metadata
- Authors
- Reilly, M. C., Gerlier, L., Brabant, Y., & Brown, M.
- ORCID
- Gerlier, Laetitia
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 30
- Issue
- 2
- Pages
- 393-404
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2107743584
- Cited by
- 196
- References
- 41
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 19 · 2023: 16 · 2022: 15 · 2021: 13 · 2020: 14 · 2019: 14 · 2018: 11 · 2017: 3 · 2016: 10 · 2015: 7 · 2014: 13 · 2013: 5 · 2012: 5
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- Crohn's disease, Work Productivity and Activity Impairment, labor productivity, activity impairment, absenteeism, presenteeism, disease severity, health-related quality of life, remission, questionnaire validity, responsiveness, inflammatory bowel disease, patient-reported outcomes, standardized response mean, CDAI, IBDQ, EQ-VAS, SF-36
- MeSH terms
- Absenteeism, Certolizumab Pegol, Activities of Daily Living, Adolescent, Adult, Aged, Crohn Disease, Female, Gastrointestinal Agents, Humans, Immunoglobulin Fab Fragments, Male, Middle Aged, Polyethylene Glycols, Predictive Value of Tests, Quality of Life, Surveys and Questionnaires, Severity of Illness Index, Time Factors, Reproducibility of Results, Treatment Outcome, Cost of Illness, Sick Leave, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
